Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage live biotherapeutics company that regularly issues news about its microbiome-based drug programs, regulatory interactions, and corporate developments. The company focuses on oral live biotherapeutics for medically vulnerable patient populations, particularly adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) and other high-risk groups.
News about Seres often centers on its lead investigational candidate SER-155, including Phase 1b clinical data showing a significant reduction in bacterial bloodstream infections, systemic antibiotic exposure, and febrile neutropenia in allo-HSCT patients compared with placebo. Updates also cover regulatory designations for SER-155, such as Breakthrough Therapy and Fast Track status, and detailed feedback from the U.S. Food and Drug Administration on the design of a planned Phase 2 study.
Investors and followers of MCRB can expect announcements on clinical trial progress, investigator-sponsored studies in areas like immune checkpoint inhibitor–related enterocolitis, and research presentations at major medical meetings. Seres also issues press releases on mechanistic publications for its live biotherapeutics, including VOWST™, and on data generated from its MbTx® platform that support its broader live biotherapeutic strategy.
In addition to R&D updates, Seres publishes news on cost-reduction actions, cash runway expectations, leadership changes, and efforts to secure capital or partnerships to advance its pipeline. For those tracking MCRB, this news feed provides a centralized view of program milestones, scientific data, regulatory interactions, and corporate actions that shape the company’s live biotherapeutics portfolio.
Seres Therapeutics (Nasdaq: MCRB) announced new post hoc data from the SER-155 Phase 1b trial will be presented orally at IDWeek 2025 on October 20, 2025. The presentation reports differences between SER-155 and placebo in bacterial and fungal bloodstream infection (BSI) pathogens, clinical BSI outcomes, antibacterial prophylaxis use, and antimicrobial resistance patterns.
Key disclosed result: in the randomized, double-blind Phase 1b cohort, SER-155 reduced BSIs by 77% and lowered systemic antibiotic use and febrile neutropenia. The company said it received constructive FDA feedback on a well-powered Phase 2 design and is finalizing the protocol while pursuing capital to advance SER-155 and its live biotherapeutics portfolio.
Seres Therapeutics (NASDAQ:MCRB) has received constructive FDA feedback on its Phase 2 study protocol for SER-155, a breakthrough therapy-designated treatment for preventing bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant.
The planned Phase 2 study will be placebo-controlled with 248 participants, focusing on preventing bloodstream infections through 30 days post-transplant. An interim analysis is expected within 12 months of study initiation.
To extend its cash runway into Q2 2026, Seres is implementing cost reduction measures, including a 25% workforce reduction with severance costs of $1.0-$1.4 million. The company continues seeking capital to advance the SER-155 study and its broader portfolio.
Seres Therapeutics (Nasdaq: MCRB), a live biotherapeutics company, will participate in the H.C. Wainwright Global Investment Conference in New York City. The company's management will deliver a corporate presentation on September 8, 2025 at 3:00 p.m. ET.
A webcast replay of the presentation will be accessible on the Seres website approximately two hours after the event and will remain available for 21 days.
Seres Therapeutics (NASDAQ: MCRB) reported Q2 2025 financial results and business updates. The company submitted a Phase 2 study protocol to FDA for SER-155, targeting bloodstream infection prevention in stem cell transplant patients. The planned study will enroll 248 participants with interim analysis expected within 12 months of initiation.
Key financial highlights include a net loss of $19.9 million in Q2 2025, reduced from $26.2 million in Q2 2024. The company received a $25 million payment from Nestlé Health Science in July 2025 and expects to fund operations into Q1 2026. Management changes include the appointment of Thomas DesRosier and Marella Thorell as co-CEOs, effective August 1, 2025.
Seres Therapeutics (NASDAQ: MCRB), a leading live biotherapeutics company, has scheduled its second quarter 2025 financial results and business updates conference call for August 6, 2025, at 8:30 a.m. ET.
The company will host both a conference call and live audio webcast. Investors can access the call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 3641971. The webcast will be available in the "Investors and News" section of the Seres website and will remain archived for approximately 21 days.
Seres Therapeutics (NASDAQ:MCRB) announced a significant leadership transition as Thomas DesRosier and Marella Thorell are appointed co-CEOs, effective July 31, 2025, following current CEO Eric Shaff's departure. Both executives will retain their existing roles as Chief Legal Officer and Chief Financial Officer, respectively.
The company is actively engaging with multiple parties for potential business development and partnerships to secure additional capital for advancing SER-155, which has received Breakthrough Therapy designation. The drug showed promising Phase 1b results with a 77% relative risk reduction in bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT).
Eric Shaff, who led Seres for a decade and achieved the first-ever FDA-approved oral microbiome therapy, will remain on the company's Board of Directors.
Seres Therapeutics (NASDAQ: MCRB) reported Q1 2025 financial results and provided updates on its lead candidate SER-155. The company plans to submit a Phase 2 study protocol to FDA for SER-155, targeting the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant. Previous Phase 1b data showed a 77% relative risk reduction in bloodstream infections.
Financial highlights include net income of $32.7 million for Q1 2025, compared to a net loss of $32.9 million in Q1 2024. The company had $58.8 million in cash as of March 31, 2025, with runway into Q1 2026. A $25 million payment from Nestlé is expected in July 2025. The company recently completed a 1-for-20 reverse stock split and regained Nasdaq compliance.
Seres Therapeutics announced three poster presentations at the upcoming 2025 Digestive Disease Week (DDW) Conference in San Diego. The company will showcase new research on live biotherapeutics for treating inflammatory and immune diseases, including ulcerative colitis and Crohn's disease.
The presentations include two new research posters focusing on:
- Characterization of IBD microbiomes to evaluate candidate biomarkers
- Biomarkers of microbiome disruption for patient selection in UC trials
A third poster will present previously disclosed results from the SER-155 Phase 1b study, which demonstrated positive outcomes in promoting intestinal barrier integrity and modulating inflammatory responses. Seres is actively seeking partnerships to advance their biotherapeutics development in inflammatory and immune diseases.
Seres Therapeutics (Nasdaq: MCRB), a leading live biotherapeutics company, has scheduled a conference call and live audio webcast for May 7, 2025, at 8:30 a.m. ET to discuss their first quarter 2025 financial results and provide business updates.
Investors can access the conference call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 4618787. The webcast will be available in the 'Investors and News' section of the Seres website and will remain archived for approximately 21 days after the event.